
Sign up to save your podcasts
Or


Dr. Jeff Burns talks with Dr. Lon Schneider about the development of ARIA in the Phase 3 EMERGE and ENGAGE trials that led to the FDA's accelerated approval of aducanumab for the treatment of Alzheimer disease.
By American Academy of Neurology4.7
285285 ratings
Dr. Jeff Burns talks with Dr. Lon Schneider about the development of ARIA in the Phase 3 EMERGE and ENGAGE trials that led to the FDA's accelerated approval of aducanumab for the treatment of Alzheimer disease.

319 Listeners

496 Listeners

50 Listeners

3,343 Listeners

12 Listeners

1,147 Listeners

23 Listeners

193 Listeners

513 Listeners

134 Listeners

369 Listeners

189 Listeners

373 Listeners

316 Listeners

82 Listeners